Ms. Pohlman advises domestic and foreign clients in all aspects of intellectual property in her field, with her particular focus in the areas of molecular biology, immunology, pharmaceutical agents and formulations, DNA/RNA based diagnostics, CRISPR, second medical uses and dosing regimens. A main part of her practice is oppositions and prosecution before the European Patent Office, where she has consistently obtained favorable results for her clients.

She has served as lead counsel in notable opposition cases relating to patents for blockbuster drugs and groundbreaking technologies including, more recently, Tecfidera®, Tysabri®, and attacking and defending CRISPR patents, as well as numerous antibody-related oppositions (adalimumab, herceptin, bevacizumab, pertuzumab).  Ms. Pohlman handles prosecution in the pharmaceutical and biotechnology fields for more than two decades and can deliver complex portfolio strategies that add value.